Research predicts rise in IBD in developing world
24 Oct 2017 --- For the last century, inflammatory bowel disease (IBD) has been a challenge for patients and the medical community in the Western world. Now, research published in The Lancet by Dr. Gilaad Kaplan shows that countries outside the Western world may now be facing the same pattern of increasing IBD rates. “Over the past 100 years, the incidence of IBD in western countries has climbed and then plateaued,” says Kaplan, an associate professor at the Cumming School of Medicine. “Our research shows that countries outside the western world now appear to be in the first stage of this sequence.” IBD affects over 0.3 percent of the population in North America and Europe, according to the University of Calgary press release. “IBD is a modern disease, growing in prevalence in North America, Europe and Australia since the 1950s,” says Kaplan. “As countries in Asia, South America and the Middle East have become industrialized, IBD has emerged, and its incidence is rising dramatically. At the turn of the 21st century, it became a global disease.” Done in collaboration with Siew Ng, Ph.D., at the Chinese University of Hong Kong, the research brings together data from all population-based studies reporting on the incidence or prevalence of IBD since 1990. “As newly industrialized countries become more westernized, we can clearly see that the incidence of IBD is also rapidly rising,” says Ng. As IBD becomes a global problem, Kaplan and Ng are hopeful that a coordinated solution to prevent and treat IBD around the world could be possible. “Future research should focus on identifying environmental risk factors observed during the early stages of industrialization,” says Ng. Kaplan agrees: “Research into environmental intervention that helps to prevent IBD should be prioritized.” Kaplan presented the findings at the World Congress of Gastroenterology on October 16 in Orlando, Florida, US. “The increasing prevalence of IBD will challenge clinicians and health policy-makers,” says Kaplan. “Globally, we need to prepare our clinical infrastructure and personnel to manage this complex and costly disease.” To contact our editorial team please email us at editorial@cnsmedia.com
Related ArticlesHealth & Nutrition News Campaigners condemn ASA reversal of junk food advert ban after Kellogg’s lobbies for U-turn21 Nov 2018 --- Breakfast cereal giant Kellogg’s has welcomed the reversal of a UK Advertising Standards Agency (ASA) junk food advert ban and called from the company to re-examine the initial decision. Kellogg’s says the original judgment could have had “potential consequences” for the industry, disincentivizing food companies from developing better-for-you alternatives. The U-turn, which followed an independent review, has sparked criticism from obesity campaigners who originally brought the action against the granola advert. Health & Nutrition News US start-up No Cow introduces low sugar energy bar with patented caffeine ingredient21 Nov 2018 --- US active nutrition start-up No Cow is launching its No Cow Energy Bars, following a partnership with General Mills. The energy bars are low in sugar (one gram) and contain 45mg of Coffee Bean Flour, an innovative, patented caffeine source that provides sustainable energy that is the equivalent of half a cup of coffee. No Cow Energy Bars contain oats, nuts, and almond butter and 12g of protein per serving. Moreover, they bars are gluten-free, soy-free and non-GMO. Health & Nutrition News Resistant starch for athletic performance: Australian start-up launches gut hydration system21 Nov 2018 --- Australia-based Flinders University start-up, Preserve Health, has launched a two-step hydration system backed by more than 20 years of medical research between Flinders and Yale Universities. The system, called PREPD, uses a unique resistant starch that has been identified as a key factor in promoting hydration in the gut. Health & Nutrition News The next infant formula staple? NZMP eyes milk fat globule membrane potential21 Nov 2018 --- As scientific understanding of infant development evolves, the industry is seeing growing opportunities for infant nutrition formulas that come as close to human breast milk as possible, and which benefit aspects such as brain and immune health. In this space, NZMP, Fonterra’s B2B ingredients business, is making strides in uncovering the potential of milk fat globule membrane (MFGM). Health & Nutrition News “Breakthrough” treatment seeks to protect people with peanut allergies through exposure to peanut protein20 Nov 2018 --- Medical researchers have developed a new treatment for protection against accidental exposure to peanut. Although the treatment is not a “quick fix,” the researchers note their study results show it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time. More Articles |
